LabCorp will be the exclusive provider of the test, which uses next-generation sequencing to look for actionable mutations cell-free DNA in NSCLC patients.
Investigators from the pharma concluded that most liquid biopsy false positives and negatives could be traced to technical specifics of individual tests.
The institutes will send patients samples to Resolution Bioscience, which will sequence circulating tumor DNA to identify the genetic causes of drug resistance.
The firm is moving into a larger facility after its first full year of profitability and planning new hires to support its plans to bring liquid biopsy kits through the FDA.
A circulating tumor DNA analysis identified somatic mutations in more than 64 percent of advanced non-small cell lung cancer cases, including some drug targets.
